Glen P. Marszalowicz, Ph.D.
810 Autumn River Run
Philadelphia, PA 19128
732-513-3575
gmarsz@gmail.com
EDUCATION:
Ph.D. in Biomedical Science. June 2014
Drexel University. School of Biomedical Engineering, Science, and Health Systems. Philadelphia, PA.
B.A. in Biology. Minor in English. May 2003
Rutgers, The State University of New Jersey. New Brunswick, NJ.
EXPERIENCE:
Ph.D. Thesis Research. Thomas Jefferson University. Laboratory of Scott A. Waldman, M.D., Ph.D. Oct 2007- June 2014
Developed and generated specific immunotoxin-mediated therapy for colorectal cancer metastasis. Skills: antibody development,
hybridoma and tissue culture procedures, confocal microscopy, IHC, ELISA, Western, PCR, 125I-radiolabeling, ligand binding assays
(membrane or cells), RIA, and radio-isotope laboratory management. Mentored and managed summer students annually. Publications
attached.
Teaching Assistant. Drexel University. June 2007 - June 2014
Instructed, guided, and evaluated undergraduate students in the Biomedical Engineering program in both the theory and application of
physiological measurements such as EMG, EKG, and EOG using Biopac. Solely responsible for class structure, lectures, labs, and
grading, with tenured professors playing only administrative roles. Engaged in a more conventional TA role in the Biomedical
Electronics course, creating operational amplifiers, filters, basic circuits, as well as in the Computational Bioengineering course,
employing MATLAB to analyze protein networks, cell division, therapeutic models.
Research Biologist. Bracco Research USA. July 2005 - Dec 2006
Pre-clinical development and in vivo bio-distribution. Tested radio-therapeutic drug efficacy on xeno-grafted human prostate cancer
metastatic cell lines including PC3, LNCaP, and DU145. Skills included: 177Lu, 153Gd, 125I, 67Ga bio-distribution via tail vein injection,
xeno-grafting, allo-grafting, necropsy, transponder labeling, cryostat use, radiation safety, data entry/review, and aseptic vivarium
technique and maintenance.
Cardio Infusion Telemetry Toxicology Surgeon. Huntingdon Life Sciences. June 2003 - Aug 2004
In addition to excelling in acquisition and use of surgical and technical skills, managed the running of up to three studies simultaneously,
including communicating pertinent information among technicians, a group leader, and study directors. Specific skills included: GLP,
data acquisition and review, animal husbandry, dosing IM, IV, SQ, PO, NG, gavage, IV via pump. Surgical proficiencies included aseptic
technique, anesthesia, implantation of catheters, telemetry devices, venous access ports, reparation of all preceding procedures. Skills
apply to rodent, canine, non-human primate, and mini-pig.
SOFTWARE:
Zeiss LSM, Biopac, Prism, FlowJo, ImageJ, Illustrator, Photoshop, Word, Excel, PowerPoint
HONORS:
Teaching Excellence Award (2014)
Rutgers Outstanding Merit Scholar (1999-2003)
Edward J. Bloustein Commended Scholar (1999-2003)
Eagle Scout (1999)
PERSONAL:
Self-taught guitarist, photographer, 1968 Ford Mustang mechanic, all-around tinkerer.
PUBLICATIONS
PAPERS
1. GUCY2C lysosomotropic endocytosis delivers immunotoxin therapy to metastatic colorectal cancer.
Glen P. Marszalowicz, Adam E. Snook, Michael S. Magee, Dante Merlino, Lisa D. Berman-Booty and Scott A.
Waldman. Oncotarget, 5(19), 9460-9471. 2014 Oct 15.
2. Intestinal GUCY2C prevents TGF-β secretion coordinating desmoplasia and hyperproliferation in
colorectal cancer. Gibbons AV, Lin JE, Kim GW, Marszalowicz GP, Li P, Stoecker BA, Blomain ES, Rattan S,
Snook AE, Schulz S, Waldman SA. Cancer Res. 2013 Nov 15;73(22):6654-66. doi: 10.1158/0008-5472.CAN-130887. Epub 2013 Oct 1.
3. Epitope-targeted cytotoxic T cells mediate lineage-specific antitumor efficacy induced by the cancer
mucosa antigen GUCY2C. Snook AE, Magee MS, Marszalowicz GP, Schulz S, Waldman SA. Cancer Immunol
Immunother. 2012 May;61(5):713-23. doi: 10.1007/s00262-011-1133-0. Epub 2011 Nov 6.
4. A uroguanylin-GUCY2C endocrine axis regulates feeding in mice. Valentino MA, Lin JE, Snook AE, Li
P, Kim GW, Marszalowicz G, Magee MS, Hyslop T, Schulz S, Waldman SA. J Clin Invest. 2011 Sep;121(9):357888. doi: 10.1172/JCI57925. Epub 2011 Aug 25.
5. The hormone receptor GUCY2C suppresses intestinal tumor formation by inhibiting AKT signaling.
Lin JE, Li P, Snook AE, Schulz S, Dasgupta A, Hyslop TM, Gibbons AV, Marszlowicz G, Pitari GM, Waldman
SA. Gastroenterology. 2010 Jan;138(1):241-54. doi: 10.1053/j.gastro.2009.08.064. Epub 2009 Sep 6.
6. Guanylyl cyclase C as a biomarker for targeted imaging and therapy of metastatic colorectal cancer.
Chang C, Marszlowicz G, Waldman Z, Li P, Snook AE, Lin JE, Schulz S, Waldman SA. Biomark
Med.;3(1):33-45. doi: 10.2217/17520363.3.1.33. 2009 Feb
REVIEWS
1. Immunotherapeutic strategies to target prognostic and predictive markers of cancer. Magee MS, Snook
AE, Marszalowicz GP, Waldman SA. Biomark Med. 2013 Feb;7(1):23-35. doi: 10.2217/bmm.12.110. Review.
2. Bacterial heat-stable enterotoxins: translation of pathogenic peptides into novel targeted diagnostics
and therapeutics. Lin JE, Valentino M, Marszalowicz G, Magee MS, Li P, Snook AE, Stoecker BA, Chang C,
Waldman SA. Toxins (Basel). 2010 Aug;2(8):2028-54. doi: 10.3390/toxins2082028. Epub 2010 Aug 5. Review.
3. GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome? Li P, Lin JE,
Marszlowicz GP, Valentino MA, Chang C, Schulz S, Pitari GM, Waldman SA. Drug News Perspect. 2009 JulAug;22(6):313-8. doi: 10.1358/dnp.2009.22.6.1395254. Review.